Guide Medicinal Product

Anticoagulant: Sources and notes

- Heir C. et al., How to reduce the risk of VKAs? Use of prescription software. Rev. Prat. Med. Gen., 2007; 21: 42-45.
Hyers YM et al., Chest 2001; 119: 1765-1935.

- Non-valvular atrial fibrillation: What place for non-antivitamin oral anticoagulants K: apixaban (Eliquis®), dabigatran (Pradaxa®) and rivaroxaban (Xarelto®). High Authority of Health. Good use of the drug, July 2013.

- Nacora-Switch study, 2014.

Popular Posts

Category Guide Medicinal Product, Next Article

Generic Drugs: Generic Drugs and Third Party Payers - Guide Medicinal Product
Guide Medicinal Product

Generic Drugs: Generic Drugs and Third Party Payers

Doctors do not have to prescribe generic drugs. Instead, they are motivated by Health Insurance to prescribe drugs with an International Nonproprietary Name (INN) , that is, by specifying the name of the molecule. From 2015 , this type of prescription should be mandatory in France: doctors will not prescribe the originator, but the molecule
Read More
Anticoagulant: The advice of the specialist doctor - Guide Medicinal Product
Guide Medicinal Product

Anticoagulant: The advice of the specialist doctor

Professor Gérard Helft is a cardiologist at the Pitié-Salpêtrière Heart Institute (Paris). This specialist doctor brings many tips ... Why should patients taking an anticoagulant be well informed? The information communicated to the patients is absolutely essential because the slightest difference in taking this medicine can have serious consequences. Ho
Read More
AIDS: progress thanks to generic drugs! - Guide Medicinal Product
Guide Medicinal Product

AIDS: progress thanks to generic drugs!

Today around 34 million people in the world are living with HIV ... and only 50% of them are HIV-positive . Although the percentage of HIV-positive adults has stabilized, the number of new infections and AIDS deaths remains far too high! Fortunately, progress is being made in research on the disease, as well as on new treatments, but also for better access to care by the poorest populations, which is a major step to reduce this disease worldwide
Read More